Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Universidad Rey Juan Carlos | OTHER |
Not provided
Not provided
Not provided
Not provided
A case-control study will be conducted to analyze the differences in BDNF levels between patients with chronic pain and asymptomatic people.
Brain-derived neurotrophic factor (BDNF) is considered a biomarker of brain plasticity. Since different alterations in brain plasticity have been found in chronic pain patients, the investigators want to study whether there are differences at the molecular level in this population compared to an asymptomatic population in order to be able to accurately measure the impact of different physiotherapy interventions in an objective way.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chronic Pain Patient | A blood draw is to be performed to analyze peripheral BDNF. |
| |
| Asymptomatic subject | A blood draw is to be performed to analyze peripheral BDNF. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BDNF analysis (Elisa KIT) | Genetic | Analysis of peripheral BDNF will be performed |
|
| Measure | Description | Time Frame |
|---|---|---|
| BDNF Levels | Brain Derived Neurotrophic Factor: Pierce NeutrAvidin-coated high-capacity plates (ThermoFisher Scientific; 15509) will incubate for two hours at RT with 200 µl of 14 µg/ml biotin-conjugated mAb-#1 diluted in phosphate buffer (0.1% Triton X-100 in 0.1 M phosphate buffer: 0.1 M KH2PO4 and 0.1 M Na2HPO4; pH 7.6). Plates will then washed three times with blocking buffer [1% bovine serum albumin (BSA); Sigma A2153 in phosphate buffer], followed by the addition of 150 µl phosphate buffer. A total of 50 µl of either standards or diluted samples (both in blocking buffer) will then added to the plate followed by incubation for 3 h at RT on a rotary shaker. | 3 hours |
| Pain Intensity | Pain intensity assessed with the 100 mm Visual Analog Scale, in which the patient is asked about his or her pain level at that moment, with one side being "no pain" and the other extreme being "the worst pain imaginable" | 3 hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
subjects will be selected if they have been suffering from musculoskeletal pain (not oncological) for at least 3 months.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Raúl Ferrer, PhD | Contact | +34655412476 | raul.ferrer@lasallecampus.es |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Irf Cseuls | Recruiting | Madrid | 28053 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059350 | Chronic Pain |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
BDNF levels will be measured through a blood sample taken by a nurse and analysed by a biochemist. Blood collection has been chosen over saliva analysis because the former has been shown to be the most reliable method for measuring this neurotrophin at the peripheral level.